Payment overview · 2025
General Payments
$1,169.34
54 reported records · 17 companies
Healthcare provider profile · identity verified
Arun Kumar Gupta, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MERRICK, NY · NPI 1962444802
Verified facts
What the public records show
CMS Open Payments records show Arun Kumar Gupta, M.D. received $1,169.34 in general payments during 2025 across 54 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Eliquis by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Xarelto by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 238 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $231.75 | 19.8% | 12 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $200.42 | 17.1% | 13 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $186.64 | 16.0% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $80.32 | 6.9% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $68.12 | 5.8% | 3 | 2025 |
| MEDICOMP INC | Unresolved — no canonical attribution shown | $57.00 | 4.9% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $50.91 | 4.3% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $47.73 | 4.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.59 | 3.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.14 | 3.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.74 | 3.5% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $26.00 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.50 | 2.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.93 | 1.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.56 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.67 | 1.3% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.32 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,169.34 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $231.75 | 12 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $200.42 | 13 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $186.64 | 5 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $186.64 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $80.32 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $68.12 | 3 | 2025 |
Source payment records
|
|||||
| TELEPATCH CARDIAC MONITOR Normalized: telepatch cardiac monitor |
Device | MEDICOMP INC | $57.00 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $50.91 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $47.73 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $40.74 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 238 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
238 | 61 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
111 | 30 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
73 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
238 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 165 |
| Metoprolol Succinate | Metoprolol Succinate | 421 | 128 |
| Losartan Potassium | Losartan Potassium | 309 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 291 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 252 | 85 |
| Eliquis | Apixaban | 238 | 61 |
| Furosemide | Furosemide | 165 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 37 |
| Ezetimibe | Ezetimibe | 133 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 44 |
| Xarelto | Rivaroxaban | 111 | 30 |
| Atenolol | Atenolol | 87 | 22 |
| Carvedilol | Carvedilol | 87 | 26 |
| Metformin Hcl | Metformin Hcl | 76 | 31 |
| Entresto | Sacubitril/Valsartan | 73 | 22 |
| Spironolactone | Spironolactone | 69 | 23 |
| Simvastatin | Simvastatin | 67 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 65 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 25 |
| Ozempic | Semaglutide | 59 | suppressed |
| Repatha Sureclick | Evolocumab | 58 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 56 | 17 |
| Sertraline Hcl | Sertraline Hcl | 52 | 20 |
| Farxiga | Dapagliflozin Propanediol | 51 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 17 |
| Gabapentin | Gabapentin | 46 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 45 | 15 |
| Midodrine Hcl | Midodrine Hcl | 44 | 16 |
| Allopurinol | Allopurinol | 42 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 14 |
| Methylprednisolone | Methylprednisolone | 40 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Lisinopril | Lisinopril | 31 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | 11 |
| Jardiance | Empagliflozin | 29 | 11 |
| Valsartan | Valsartan | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | 16 |
| Telmisartan | Telmisartan | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | 11 |
| Mupirocin | Mupirocin | 25 | 20 |
| Digoxin | Digoxin | 24 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Eplerenone | Eplerenone | 18 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 18 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 16 | suppressed |
| Multaq | Dronedarone Hcl | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,169.34 · 54 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | ABRYSVO, COMIRNATY, CONTRAVE, ELIQUIS, Kerendia, LEQVIO, LOKELMA, OPSUMIT, Ozempic, PREVNAR 20, REPATHA, REZDIFFRA, TELEPATCH CARDIAC MONITOR, TRELEGY ELLIPTA, TREMFYA, UPTRAVI, VERQUVO, VOQUEZNA, VYEPTI, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error